Related references
Note: Only part of the references are listed.A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Hidetoshi Hayashi et al.
CLINICAL CANCER RESEARCH (2022)
INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Egbert F. Smit et al.
FUTURE ONCOLOGY (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
K. Nakagawa et al.
Journal of Thoracic Oncology (2021)
Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
E. B. Garon et al.
ANNALS OF ONCOLOGY (2021)
Amivantamab: First Approval
Yahiya Y. Syed
DRUGS (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
Kenichi Suda et al.
CELLS (2021)
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du et al.
INNOVATION (2021)
CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study.
Dong-Wan Kim et al.
CANCER RESEARCH (2021)
Combination of Crizotinib and Osimertinib in T790M+EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
Miriam Blasi et al.
CASE REPORTS IN ONCOLOGY (2021)
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro et al.
NATURE CANCER (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G. R. Oxnard et al.
ANNALS OF ONCOLOGY (2020)
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
Kohsuke Isomoto et al.
CLINICAL CANCER RESEARCH (2020)
The Evolving Landscape of Resistance to Osimertinib
Adam J. Schoenfeld et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
Hidenobu Ishii et al.
THORACIC CANCER (2020)
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
Justin A. Chen et al.
JOURNAL OF THORACIC DISEASE (2020)
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V. A. Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2020)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort
Sally C. Lau et al.
CLINICAL LUNG CANCER (2019)
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
Jeffrey H. Becker et al.
CANCER RESEARCH (2019)
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Michael Offin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Keunchil Park et al.
LUNG CANCER (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Yuuri Hashimoto et al.
CLINICAL CANCER RESEARCH (2019)
First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
Hongwei Zhang et al.
PLOS ONE (2019)
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Zhonghan Zhang et al.
CANCER COMMUNICATIONS (2019)
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Myung-Ju Ahn et al.
CANCER (2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters et al.
CLINICAL CANCER RESEARCH (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
Namita Sharma et al.
CANCER TREATMENT REVIEWS (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Third generation EGFR TKIs: current data and future directions
Chee-Seng Tan et al.
MOLECULAR CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
Maria I. Toki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical relevance of PD-L1 expression and CD8+T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
Si-yang Liu et al.
LUNG CANCER (2018)
LBA8Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
B C Cho et al.
ANNALS OF ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions
Feng-Che Kuan et al.
ONCOTARGET (2017)
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
Tony S. K. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Silvia La Monica et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert Brody et al.
LUNG CANCER (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
Ling Peng et al.
ONCOTARGETS AND THERAPY (2017)
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong-Yi Dong et al.
ONCOIMMUNOLOGY (2017)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Allyson J. Ocean et al.
CANCER (2017)
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
K. Haratani et al.
ANNALS OF ONCOLOGY (2017)
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
Toshio Shimizu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Shuhang Wang et al.
CANCER LETTERS (2017)
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M. Schuler et al.
ANNALS OF ONCOLOGY (2016)
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
K. Yonesaka et al.
ONCOGENE (2016)
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
Meghan Shea et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
Janette Greenhalgh et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
Koichi Azuma et al.
ESMO OPEN (2016)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N. Starodub et al.
CLINICAL CANCER RESEARCH (2015)
Non-small-cell lung cancer
Cesare Gridelli et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang et al.
ACTA PHARMACEUTICA SINICA B (2015)
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Christiane R. Maroun et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-na ve patient: A report of three cases
Fumihiro Yamaguchi et al.
ONCOLOGY LETTERS (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
The Role of STAT3 in Non-Small Cell Lung Cancer
Daijiro Harada et al.
CANCERS (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma
Aigui Jiang et al.
ONCOLOGY LETTERS (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Pathogenesis of lung cancer signalling pathways: roadmap for therapies
E. Brambilla et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
James Bean et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
ErbB3 mRNA expression correlated with specitc clinicopathologic features of Japanese lung cancers
Osamu Kawano et al.
JOURNAL OF SURGICAL RESEARCH (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
Byoung Chul Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine
James J. Kobie et al.
JOURNAL OF IMMUNOLOGY (2006)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
